On April 24, 2024 Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, reported its upcoming presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2024 Annual Meeting taking place from May 31- June 4, 2024, in Chicago, IL (Press release, Carisma Therapeutics, APR 24, 2024, View Source [SID1234642308]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the poster presentation at ASCO (Free ASCO Whitepaper) 2024 are below:

Poster Title: A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors
Session Title: Developmental Therapeutics—Immunotherapy
Abstract Number: TPS2682
Session Date & Time: Saturday, June 1, 2024, 9:00 AM-12:00 PM CDT

The poster presented at ASCO (Free ASCO Whitepaper) 2024 will be available online in the "Publications" section of Carisma’s website at View Source following the start of the poster session.